BioNumerik Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1992-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://bionumerik.com
Clinical Trials
12
Active:6
Completed:6
Trial Phases
3 Phases
Phase 1:2
Phase 2:2
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 3
3 (42.9%)Phase 1
2 (28.6%)Phase 2
2 (28.6%)Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin
Phase 3
Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: Placebo in combination with cisplatin and docetaxel or paclitaxelDrug: Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- BioNumerik Pharmaceuticals, Inc.
- Target Recruit Count
- 540
- Registration Number
- NCT00966914
Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- BioNumerik Pharmaceuticals, Inc.
- Target Recruit Count
- 509
- Registration Number
- NCT00477282
Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer
Phase 1
Completed
- Conditions
- CarcinomaCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2004-12-02
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- BioNumerik Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00097903
- Locations
- 🇺🇸
Ellis Fischel Cancer Center, Columbia, Missouri, United States
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
- First Posted Date
- 2003-06-12
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- BioNumerik Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT00062491
- Locations
- 🇺🇸
For Information call 210-614-1701 for a site near you, Tampa, Florida, United States
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
Phase 2
Completed
- Conditions
- Brain NeoplasmsMalignant Neoplasms, BrainBrain Tumors
- Interventions
- First Posted Date
- 2003-06-12
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- BioNumerik Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00062478
- Locations
- 🇺🇸
For Information call 210-614-1701 for a site near you, Durham, North Carolina, United States
- Prev
- 1
- 2
- Next
News
No news found